Silence Therapeutics plc (SLN)
NASDAQ: SLN · Real-Time Price · USD
7.70
-0.12 (-1.53%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Silence Therapeutics Revenue
In the year 2025, Silence Therapeutics had annual revenue of $559.00K, down -98.71%. Silence Therapeutics had revenue of $34.00K in the quarter ending December 31, 2025, a decrease of -99.87%.
Revenue (ttm)
$559.00K
Revenue Growth
-98.71%
P/S Ratio
650.63
Revenue / Employee
$6,352
Employees
88
Market Cap
363.70M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 559.00K | -42.70M | -98.71% |
| Dec 31, 2024 | 43.26M | 11.62M | 36.71% |
| Dec 31, 2023 | 31.64M | 9.99M | 46.12% |
| Dec 31, 2022 | 21.66M | 4.84M | 28.82% |
| Dec 31, 2021 | 16.81M | 9.33M | 124.73% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Puma Biotechnology | 228.37M |
| Autolus Therapeutics | 75.39M |
| X4 Pharmaceuticals | 35.11M |
| Opus Genetics | 14.20M |
| Ovid Therapeutics | 7.25M |
| Armata Pharmaceuticals | 4.90M |
| YD Bio | 510.36K |
SLN News
- 7 weeks ago - Silence Therapeutics Highlights Recent Business Achievements and Reports Fourth Quarter and Full Year 2025 Financial Results - Business Wire
- 4 months ago - Silence Therapeutics Announces Leadership Changes - Business Wire
- 5 months ago - Silence Therapeutics to Participate in Fireside Chat at Jefferies Global Healthcare Conference - Business Wire
- 6 months ago - Silence Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 6 months ago - Silence Therapeutics Completes Enrollment in SANRECO Phase 2 Study of Divesiran for Polycythemia Vera (PV) - Business Wire
- 8 months ago - Silence Therapeutics to Participate in September Investor Conferences - Business Wire
- 9 months ago - Silence Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - Business Wire
- 11 months ago - Silence Therapeutics Presents Additional Phase 1 Data Highlighting Promise of Divesiran as the Potential First-in-Class siRNA Treatment for Polycythemia Vera - Business Wire